Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients

Inclusion Criteria: * Participant is able to understand and provide informed consent. * Documented HIV infection (by any licensed enzyme-linked immunosorbent assay \[ELISA\] and confirmation by Western Blot, positive HIV antibody (ab) indirect fluorescent antibody (IFA), or documented history of detectable HIV-1 RNA). * Participant is 18 years of age or older. * CD4+ T-cell count greater than or equal to 200/µL at any time in the 26 weeks prior to enrollment. * Most recent HIV-1 RNA less than 50 copies RNA/mL. Eligibility at the time of enrollment will be determined based on the most recent HIV-1 RNA, not more than 26 weeks prior to enrollment. Subjects who require a switch in combination antiretroviral therapy (cART) regimen to become study eligible must also have an eligible HIV-1 RNA result post change in cART. * Participant meets standard listing criteria for placement on transplant waiting list. * For participants with an HIV+ deceased donor: * No active opportunistic infections. * Concurrence by the study team that based on medical history and ART, viral suppression can be achieved in the recipient post-transplant. * Must be enrolled in an Institutional Review Board (IRB) approved research protocol that fulfills the requirements of the DHHA Hope Act Policy (see the protocol for more information). * HIV+ deceased donor must have no evidence of invasive opportunistic complications of HIV infection, and must have a pre-implant biopsy. * Antiretroviral (ARV) Use: …